Publication:
Elabela deficiency promotes preeclampsia and cardiovascular malformations in mice

dc.contributor.coauthorHo, Lena
dc.contributor.coauthorvan Dijk, Marie
dc.contributor.coauthorChye, Sam Tan Jian
dc.contributor.coauthorMesserschmidt, Daniel M.
dc.contributor.coauthorChng, Serene C.
dc.contributor.coauthorOng, Sheena
dc.contributor.coauthorYi, Ling Ka
dc.contributor.coauthorBoussata, Souad
dc.contributor.coauthorGoh, Grace Hui-Yi
dc.contributor.coauthorAfink, Gijs B.
dc.contributor.coauthorLim, Chin Yan
dc.contributor.coauthorDunn, N. Ray
dc.contributor.coauthorSolter, Davor
dc.contributor.coauthorKnowles, Barbara B.
dc.contributor.departmentN/A
dc.contributor.kuauthorReversade, Bruno
dc.contributor.kuprofileFaculty Member
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.yokid274182
dc.date.accessioned2024-11-10T00:05:10Z
dc.date.issued2017
dc.description.abstractPreeclampsia (PE) is a gestational hypertensive syndrome affecting between 5 and 8% of all pregnancies. Although PE is the leading cause of fetal and maternal morbidity and mortality, its molecular etiology is still unclear. Here, we show that ELABELA (ELA), an endogenous ligand of the apelin receptor (APLNR, or APJ), is a circulating hormone secreted by the placenta. Elabela but not Apelin knockout pregnant mice exhibit PE-like symptoms, including proteinuria and elevated blood pressure due to defective placental angiogenesis. In mice, infusion of exogenous ELA normalizes hypertension, proteinuria, and birth weight. ELA, which is abundant in human placentas, increases the invasiveness of trophoblast-like cells, suggesting that it enhances placental development to prevent PE. The ELA-APLNR signaling axis may offer a new paradigm for the treatment of common pregnancy-related complications, including PE.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue6352
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.sponsorshipA*STAR Joint Council Organization
dc.description.sponsorshipStrategic Positioning Fund on Genetic Orphan Diseases from the Biomedical Research Council, A*STAR, Singapore
dc.description.sponsorshipFerring Research Institute Innovation Grant
dc.description.sponsorshipA*STAR Investigatorship, an EMBO We thank T. Quertermous (Stanford University, USA) for sharing the Apln and Apj knockout mice
dc.description.sponsorshipT. Veenboer (AMC, Netherlands) for assistance with human placenta samples
dc.description.sponsorshipD. Kalicharan for technical assistance with electron microscopy
dc.description.sponsorshipmembers of the Advanced Molecular Pathology Laboratory, Institute of Molecular and Cell Biology, for assistance with histopathology
dc.description.sponsorshipthe Institute of Medical Biology Microscopy Unit for assistance with imaging
dc.description.sponsorshipand the Genome Institute of Singapore sequencing facility for assistance with RNA-seq. RNA-seq data are deposited in the National Center for Biotechnology Information (NCBI) Sequence Read Archive under accession number PRJNA391361. The data reported in this manuscript are tabulated in the main paper and in the supplementary materials. The authors acknowledge financial support from the A*STAR Joint Council Organization (Young Researcher Collaborative Grant) and a Strategic Positioning Fund on Genetic Orphan Diseases from the Biomedical Research Council, A*STAR, Singapore. M.v.D. and S.B. are supported by a Ferring Research Institute Innovation Grant. B.R. is a fellow of the Branco Weiss Foundation, a recipient of the A*STAR Investigatorship, an EMBO Young Investigator, and an AAA fellow from AMC/VUmc. The authors declare no competing financial interests. B.R. and L.H. are inventors on patent application 10201605841S submitted by A*STAR, Singapore, which covers the use of ELABELA for the diagnosis and treatment of preeclampsia. The ELABELA-deficient mice and custom antibody are available from B.R. under a material transfer agreement with A*STAR, Singapore.
dc.description.volume357
dc.identifier.doi10.1126/science.aam6607
dc.identifier.eissn1095-9203
dc.identifier.issn0036-8075
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85021804387
dc.identifier.urihttp://dx.doi.org/10.1126/science.aam6607
dc.identifier.urihttps://hdl.handle.net/20.500.14288/16388
dc.identifier.wos407793600040
dc.keywordsGrowth factor
dc.keywordsExpression
dc.keywordsReceptor
dc.keywordsTissue
dc.keywordsCells
dc.keywordsAPJ
dc.languageEnglish
dc.publisherAmerican Association for the Advancement of Science (AAAS)
dc.sourceScience
dc.subjectScience
dc.titleElabela deficiency promotes preeclampsia and cardiovascular malformations in mice
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.authorid0000-0002-4070-7997
local.contributor.kuauthorReversade, Bruno

Files